Figure 7: Assessment of growth properties of ES cell-derived teratocarcinomas. | Nature Communications

Figure 7: Assessment of growth properties of ES cell-derived teratocarcinomas.

From: Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

Figure 7

(a) Plk1 mRNA and protein levels in Plk1-iKD- and Luc-iKD-ES cells (±Dox) determined by semi-quantitative RT-PCR analysis and western blot. (b) Volumes of teratocarcinomas derived from Plk1-iKD- and Luc-iKD-ES cells (inoculated on opposite flanks of the same animal) either after induction with Dox or in the absence of Dox starting with 3 days before inoculation. Significant inhibition of tumour growth (P<0.05) is indicated with an asterisk (means±s.d., n=12, for each time point). (c) Representative image of a mouse exhibiting Plk1-iKD- and Luc-iKD-ES cell-derived tumour growth on opposite flanks. (d) Total cellular protein was prepared from Plk1-iKD- and Luc-iKD-ES cell tumours and separated by SDS–PAGE for anti-Plk1, -itetR and -β-actin immunoblotting analyses (means±s.d., n=3, for each treatment). *P<0.05, Student's t-test, unpaired and two-tailed.

Back to article page